Sign Up Today and Learn More About Synthace Stock
Invest in or calculate the value of your shares in Synthace or other pre-IPO companies through EquityZen's platform.
Synthace Stock (SYNT)
Life Sciences R&D cloud platform
Synthace is a R&D cloud platform.
About Synthace Stock
Founded
2011
Total Funding
76.9M
Industries
Software, Artificial Intelligence, Financial Services
Synthace is a R&D cloud platform. Synthace aims to automate experimentation and insight sharing for scientists to share, view, and access progress with cures and therapeutics in one place.
Synthace was founded in 2011 and is headquartered in London, White City. Notable investors include Horizons Ventures, Sofinnova Partners, Amadeus Capital Partners, and Luminous Ventures.
Synthace Press Mentions
Stay in the know about the latest news on Synthace
Methods for optimisation of liquid handling processes
patents • Feb 08, 2025
SPT Labtech, Synthace Automate Drug Assay Optimization Instructions for Liquid Handlers
genengnews • Sep 06, 2024
Flamingo Therapeutics appoints new board member and more digital health hires
mobihealthnews • Apr 10, 2024
Synthace Announces Appointment of Willem Baralt as New Chairman
prnewswire • Mar 20, 2024
Synthace combines ChatGPT and digital experiments in first step toward a true AI scientist
businesswire • May 24, 2023
Synthace Management
Leadership team at Synthace
CEO
Guy Levy-Yurista
Co-founder & Chief Scientific Officer
Markus Gershater
Join now and verify your accreditation status to gain access to:
- Synthace Current Valuation
- Synthace Stock Price
- Synthace Management
- Available deals in Synthace and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Synthace Cap Table and Funding History by Share Class and Liquidity Preferences
- Synthace Revenue and Financials
- Synthace Highlights
- Synthace Business Model
- Synthace Risk Factors
- Synthace Research Report from SACRA Research
Trading Synthace Stock
How to invest in Synthace stock?
Accredited investors can buy pre-IPO stock in companies like Synthace through EquityZen funds. These investments are made available by existing Synthace shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Synthace stock?
Shareholders can sell their Synthace stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
